NCT03801707View on ClinicalTrials.gov

Utilization of Hepatitis C Positive Kidneys in Negative Recipients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 22, 2019

Primary Completion Date

April 28, 2021

Study Completion Date

April 30, 2021

Conditions
Kidney TransplantHepatitis CHCV
Interventions
DRUG

Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]

fixed dose combination medication once a day for 12 weeks for the treatment of hepatitis C

DRUG

Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]

Three tablets once a day for 12 weeks for treatment of hepatitis C

Trial Locations (1)

43210

Brenda Cuson, Columbus

All Listed Sponsors
lead

Ohio State University

OTHER

NCT03801707 - Utilization of Hepatitis C Positive Kidneys in Negative Recipients | Biotech Hunter | Biotech Hunter